Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001104659-22-013038
Filing Date
2022-02-08
Accepted
2022-02-08 08:28:16
Documents
1
Period of Report
2022-02-08

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm225802-2_3seq1.html 3  
1 OWNERSHIP DOCUMENT tm225802-2_3seq1.xml 3 5140
  Complete submission text file 0001104659-22-013038.txt   6517
Mailing Address C/O KERYX BIOPHARMACEUTICALS, INC. 750 LEXINGTON AVENUE NEW YORK NY 10022
Business Address
Oliviero James F III (Reporting) CIK: 0001434718 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-41264 | Film No.: 22599372

Mailing Address 1 BRIDGE PLAZA, SUITE 275 FORT LEE NJ 07024
Business Address 1 BRIDGE PLAZA, SUITE 275 FORT LEE NJ 07024 360-837-7232
Nuvectis Pharma, Inc. (Issuer) CIK: 0001875558 (see all company filings)

EIN.: 862405608 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations